trial

Evaluation the Efficacy "Think and Cope Positively" Program

NCTId NCT06054061
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 449 (actual)
Sponsored by Universidad Pontificia Comillas
Primary completion 2023-11-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
449 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2023-09-20
Primary completion
2023-11-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Experimental: experimental wellbeing promotion group (Think and Cope Positively)TAU

Sponsors

Universidad Pontificia ComillasLead Sponsor

Investigators

1
Rocío Caballero-Campillo, DraPrincipal Investigator

Sites

1 total
Madrid, Spain

Facts & assertions

4 sourced
Enrollment
449
Phase
NA
Primary Completion Date
2023-11-01
Status
COMPLETED
relationships
The graph out of here
drug
Experimental: experimental wellbeing promotion group (Think and Cope Positively)
drug
TAU
drug
lead_sponsor
Universidad Pontificia Comillas
company
indication
Mental Disorder
indication
Schizophrenia
indication
Mental Disorders
indication
investigator
Rocío Caballero-Campillo, Dra
person